All C Suite Event
Once registered login details will be sent closer to the event date
*This virtual event is reserved for C-Level Executives of Life Sciences PA member organizations involved in biotechnology or pharmaceutical research and development, drug discovery, medical device development, and contract research organizations involved in preclinical research. If you are unsure of your eligibility, please contact Lois Stephens at [email protected]
Join us Wednesday, May 20 for Life Sciences PA's All C Suite Event to hear Dr. Severin Schwan, Chief Executive Officer, Roche Group and Jeff Marrazzo, Chief Executive Officer, Spark Therapeutics share their insights and experiences in the life sciences.
Event Details:
Where: Studio based program with remote viewership, registration is required for the access to the event
When: Wednesday May 20, 2020
Time: 8:30am - 9:30am EST
Once registered login details will be sent closer to the event date
*There is no registration fee. The cost for this event is fully underwritten by our generous sponsors.
Speakers:
Dr. Severin Schwan, Chief Executive Officer, Roche Group
Severin Schwan was born in 1967 and is an Austrian citizen. After obtaining a degree in economics and a doctorate in law, Schwan began his career in 1993 at Roche Basel as a finance officer.
Following various management postings to Belgium, Germany and Switzerland, he moved to Singapore as regional head of the Roche Diagnostics business for Asia-Pacific in 2004. In 2006 Severin Schwan became CEO of Roche Diagnostics, the Roche Group’s global diagnostics business.
In March 2008 he was appointed CEO of the Roche Group and he became a member of the Roche Board in 2013.
Jeff Marrazzo, Chief Executive Officer, Spark Therapeutics
Jeff Marrazzo founded and has led the growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now.
Under Jeff’s leadership, Spark received regulatory approval for the first gene therapy for a genetic disease approved in both the U.S. and EU, launched the first gene therapy for a genetic disease in the United States, and established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In less than seven years, Jeff has built an organization of more than 450 colleagues while securing over $1 billion in capital and successfully orchestrating a merger with Roche. Spark has been named to the top 10 of Science Magazine’s 2019 Top Employer list, listed on the Philadelphia Business Journal’s Best Places to Work list three consecutive years and was awarded the Prix Galien for Best Biotechnology Product in 2019.
Prior to Spark, he helped build the first genetic testing benefit management up to and through the acquisition of a majority of the company’s shares by CVS Caremark. Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare.
Jeff currently serves as on the boards of the Life Science Cares Philadelphia and The Rendell Center for Civics and Civic Engagement. Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.
Jeff can be found on Twitter @JeffMarrazzo.
